Heart Failure Clinical Trial
Ferric Carboxymaltose to Improve Skeletal Muscle Metabolism in Heart Failure Patients With Functional Iron Deficiency
Summary
The purpose of this study is to better understand how body levels of iron affect the ability to exercise in patients with heart failure (HF).
Heart failure is a condition in which abnormal pumping action of the heart reduces the flow of blood to the body. Patients with heart failure may feel shortness of breath or leg fatigue when they exercise. Iron is an essential nutrient in the diet. In heart failure patients, low body levels of iron might increase shortness of breath and fatigue.
Full Description
The purpose of this prospective, double blind parallel group randomized study is to compare the effects of ferric carboxymaltose vs. placebo on skeletal muscle mitochondrial oxidative capacity, submaximal exercise tolerance, and health-related quality of life in non-anemic Heart Failure (HF) patients with functional iron deficiency.
Eligibility Criteria
Inclusion Criteria:
Symptomatic NYHA Class II-III heart failure >3 months
Guideline-recommended heart failure treatment for > 3 months
Hemoglobin >13 g/dl for men and >12 g/dl for women
Functional iron deficiency (defined as serum ferritin level <100 ng/ml or between 100 and 299 ng/ml with transferrin saturation <20%)
Left ventricular ejection fraction <40%, or left ventricular ejection fraction ≥40% with left atrial enlargement (left atrial volume index >28 ml/m2) and/or left ventricular hypertrophy (left ventricular mass index >95 g/m2 (women) or >115 g/m2 (men) determined by echocardiogram within last 24 months.
Able and willing to provide written informed consent
Exclusion Criteria:
Presence of implantable defibrillator, permanent pacemaker, other metal implant not compatible with 3TMRS/MRI, or other contraindication to 3T MRS/MRI procedures
Heart failure due to infiltrative cardiomyopathy, restrictive cardiomyopathy, or hypertrophic cardiomyopathy
Weight <50 kg or >120 kg
Coronary or cerebral atherothrombotic events in the past 6 months
Hospitalization of emergency room visit for heart failure within past 3 months
ICD shock in last 3 months
Known peripheral artery disease or ankle-brachial index <0.9 at screening visit
Exercise primarily limited by angina, lung disease or neuromuscular disease
Systolic blood pressure <100 or >160 mmHg
Heart rate <50 or >110 min-1
Estimated glomerular filtration rate <30 ml/min
Liver function tests >3 times upper limit of normal
Serum phosphate below normal limit
Pregnant or breast-feeding women
Women of child-bearing potential unwilling to use recommended contraception methods during the study
Treatment with oral iron supplements (except multivitamins) in past year
Treatment with intravenous iron in past year
Treatment with erythropoiesis stimulating agents in the past year
Known intolerance of intravenous iron
History of anaphylaxis
Participation in another clinical trial within last 30 days.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
New York New York, 10016, United States
How clear is this clinincal trial information?